Core - Biomarker Reference Laboratory (BRL)

核心 - 生物标志物参考实验室 (BRL)

• 批准号: 10705806
• 负责人: JAMES G. HERMAN
• 金额: $ 19.77万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-16 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10705806
• 关键词: Address; Baltimore; Benign; Biological Assay; Biological Markers; Biopsy; Blinded; Body Fluids; CLIA certified; Cancer Etiology; Categories; Cells; Cessation of life; Characteristics; Clinical; Collaborations; DNA Methylation; Detection; Development; Diagnostic Procedure; Diameter; Disease; Early Detection Research Network; Early Diagnosis; Ensure; Evaluation; Exhibits; Funding; Healthcare; Image; Knowledge; Laboratories; Lesion; Longterm Follow-up; Lung; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of lung; Maryland; Methodology; Methods; Methylation; Morbidity - disease rate; Nodule; Operative Surgical Procedures; Participant; Patients; Performance; Plasma; Population; Predictive Value; Procedures; Quality Control; Reagent; Reproducibility; Research Personnel; Sampling; Screening Result; Specificity; Standardization; Technology; Testing; Time; Universities; Validation; arm; assay development; biomarker development; biomarker validation; candidate marker; experience; flexibility; laboratory development; liquid biopsy; lung cancer screening; methylation biomarker; mortality; multidisciplinary; prospective; sample collection; screening; wasting

The Biomarker Reference Laboratory (BRL) will be led by Dr. Sanford Stass and as a component of the BCC will develop, refine, and standardize the biomarkers assays developed by the Biomarker Development Laboratory. This BRL is a continuation of the University of Maryland Baltimore Biomarker Reference Laboratory. UMB-BRL has for the past 15 years provided active support of the EDRN, including testing of candidate biomarkers, development of assays and technologies, and standardization of assay methods in collaboration with multiple investigators in the EDRN. The proposed BRL includes a multi-disciplinary team of directors/co- investigators and staff with broad knowledge, experience and expertise in application of technology for biomarkers including reagent and assay development and implementation, validation of laboratory methodology and assays, quality control for reagents and technologies, evaluation of accuracy, precision, reproducibility and characteristics of performance including sensitivity, specificity, and positive and negative predictive values. The BRL will bring DNA methylation biomarkers from the BDL into a CLIA compliant laboratory using developed standard operating procedures (SOPs), and extensive experience in collaborative studies in biomarker validation.

Biomarker参考实验室(BRL)将由Sanford Stass博士领导，并作为 BCC的组成部分将开发、改进和标准化所开发的生物标记物分析 由生物标志物开发实验室开发。这个BRL是牛津大学的延续 马里兰州巴尔的摩生物标志物参考实验室。UMB-BRL在过去的15年里 积极支持EDRN，包括测试候选生物标记物，制定 分析和技术，以及与多个合作的分析方法的标准化 EDRN的调查人员。拟议的BRL包括一个由董事/联席董事组成的多学科团队- 调查人员和具有广泛知识、经验和专业知识的工作人员 生物标志物技术，包括试剂和化验的开发和实施， 实验室方法和分析的验证，试剂和技术的质量控制， 评估准确度、精密度、再现性和性能特征，包括 敏感度、特异度、阳性和阴性预测值。BRL将带来DNA 甲基化生物标志物从BDL到CLIA兼容实验室使用开发的 标准操作程序(SOP)，以及在合作研究方面的丰富经验 生物标记物验证。